MVX-ONCO-2
/ Release Therap
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
October 15, 2024
MVX-ONCO-2 in Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=6 | Recruiting | Sponsor: Eugenio Fernandez | Withdrawn ➔ Recruiting | Trial completion date: Dec 2027 ➔ Oct 2029 | Trial primary completion date: Jul 2023 ➔ Oct 2025
Enrollment open • Metastases • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor
January 30, 2023
MVX-ONCO-2 in Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Maxivax SA | Not yet recruiting ➔ Withdrawn
Metastases • Trial withdrawal • Immune Modulation • Melanoma • Oncology • Solid Tumor
August 24, 2022
MVX-ONCO-2 in Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=6 | Not yet recruiting | Sponsor: Maxivax SA | Trial completion date: May 2027 ➔ Dec 2027 | Initiation date: Mar 2022 ➔ Sep 2022 | Trial primary completion date: Dec 2022 ➔ Jul 2023
Trial completion date • Trial initiation date • Trial primary completion date • Immune Modulation • Melanoma • Oncology • Solid Tumor
January 27, 2022
MVX-ONCO-2 in Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=6 | Not yet recruiting | Sponsor: Maxivax SA | Initiation date: Nov 2021 ➔ Mar 2022
Trial initiation date • Immune Modulation • Melanoma • Oncology • Solid Tumor • PCR
1 to 4
Of
4
Go to page
1